Costa Panagos will be retiring from the organization after a 24-year career at IQVIA, where he held several positions including most recently the R&DS business unit leadership role since 2022.

Syneos Health has tapped Costa Panagos to take the reins from former CEO Colin Shannon, ... Panagos recently served as president of R&D solutions at IQVIA, where he led its network expansion.

Barclays on Thursday downgraded the contract research organizations IQVIA Holdings (NYSE:IQV), ICON PLC (NASDAQ:ICLR), and Fortrea Holdings (NASDAQ:FTRE), arguing that the Trump administration’s ...

RESEARCH TRIANGLE PARK, N.C., April 21, 2025--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The ...

IQVIA’s current ratio (a measure of liquidity) at the end of fourth-quarter 2024 was pegged at 0.84, lower than the industry’s 1.93. Despite a 3.7% rise from the preceding quarter, ...

While the numbers are disappointing, IQVIA's report suggests there are signs of improvement, at least in the commitment of regulators, the pharma industry, payers, and other stakeholders to do better.

IQVIA now expects its 2024 revenue to be between $15.35 billion and $15.4 billion, versus its previous range of $15.43 billion to $15.53 billion.

IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and ...

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a ...